government orders intravenous relenza, page-8

To me it does not come down to BioCryst being listed in the US and BTA not. BioCryst's management has done a far, far better job of marketing peramivir Vs GSK/BTA's relenza

Since Sept 1 BioCryst has:

Given 6 presentations available on their BioCryst's website.

Made 8 announcements regarding peramivir

Vs

0 presentations (at least none released to shareholders)

1 announcement regarding royalties.

No announcements from BTA or GSK regarding IV relenza.


GSK website search on relenza = 132 hits

Roche website search on tamifu = 189 PAGES OF HITS ~1886 hits



Mal